The Effect of Respiratory Muscle Training for Patients With COPD and Mild Cognitive Impairment
The Therapeutic Effect of Inspiratory and Expiratory Muscle Strengthening Training on Patients With COPD and Mild Cognitive Impairment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taichung, Taiwan, 407
- Taichung Veterans General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Having definite diagnosis of COPD, namely the value of the FEV1 divided by forced vital capacity (FVC) 10 to 15 minutes after beta-2 agonist inhalation being less than 0.7.
- 2. The score of Mini-Mental State Examination (MMSE) being between 23 and 27
Exclusion Criteria:
- 1. Being not able to follow instructions on respiratory muscle training or complete the questionnaires of our study due to cognitive impairment.
- 2. Having difficulty to complete the cardiopulmonary exercise testing or the six minute walking test (6MWT) due to high risk cardiopulmonary diseases or other orthopedic conditions.
- 3. Having the diagnosis of lung cancer or history of receiving thoracoabdominal surgery
- 4. Having Body Mass Index more than 30
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Inpiratory and expiratory muscle training
The initial intensity of training was set on 30% of the MIP and MEP for inspiratory and expiratory muscle training, respectively.
The intensity was adjusted to add 5% of resistance each week
|
Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks.
Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
|
|
Active Comparator: Inspiratory muscle training
The initial resistance of the breathing trainer was also set on 30% of MIP, and the following adjustments were also in accordance to the protocol of the experimental group
|
Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks.
Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MMSE
Time Frame: 8 weeks
|
Mini-Mental State Examination
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diaphragmatic thickness fraction
Time Frame: 8 weeks
|
Diaphragmatic thickness fraction on ultrasonography
|
8 weeks
|
|
chronic obstructive pulmonary disease assessment test (CAT)
Time Frame: 8 weeks
|
questionnaire of dyspnea
|
8 weeks
|
|
diffusing capacity of the lung for carbon monoxide (DLCO)
Time Frame: 8 weeks
|
diffusing capacity of the lung for carbon monoxide (DLCO) in pulmonary function test
|
8 weeks
|
|
dead space fraction (Vd/Vt)
Time Frame: 8 weeks
|
dead space fraction (Vd/Vt) in cardiopulmonary function test
|
8 weeks
|
|
the distance walked in 6 minutes
Time Frame: 8 weeks
|
the distance walked in 6 minutes
|
8 weeks
|
|
Diaphragmatic excursion
Time Frame: 8 weeks
|
Diaphragmatic excursion on ultrasonography
|
8 weeks
|
|
forced vital capacity
Time Frame: 8 weeks
|
forced vital capacity tested in pulmonary function test
|
8 weeks
|
|
forced expiratory volume in 1 second
Time Frame: 8 weeks
|
forced expiratory volume in 1 second in pulmonary function test
|
8 weeks
|
|
forced expiratory volume in 1 second divided by forced vital capacity
Time Frame: 8 weeks
|
forced expiratory volume in 1 second divided by forced vital capacity in pulmonary function test
|
8 weeks
|
|
DLCO divided by alveolar volume (VA)
Time Frame: 8 weeks
|
DLCO divided by alveolar volume (VA) in pulmonary function test
|
8 weeks
|
|
modified Medical Research Council (mMRC)
Time Frame: 8 weeks
|
questionnaire of dyspnea
|
8 weeks
|
|
minute ventilation to carbon dioxide output (VE/VCO2) slope
Time Frame: 8 weeks
|
minute ventilation to carbon dioxide output (VE/VCO2) slope in cardiopulmonary function test
|
8 weeks
|
|
the change of oxygen saturation in 6 minutes walking test
Time Frame: 8 weeks
|
the change of oxygen saturation in 6 minutes walking test
|
8 weeks
|
|
the change of Borg scale in 6 minutes walking test
Time Frame: 8 weeks
|
the change of Borg scale in 6 minutes walking test
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yuan-Yang Cheng, Taichung Veterans General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CF18259A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.